Effectiveness of Zometa [zoledronic acid] treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO)

Trial Profile

Effectiveness of Zometa [zoledronic acid] treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO)

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer metastases; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ZEUS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jan 2011 Status changed from recruiting to completed as reported by ISRCTN.
    • 14 Feb 2008 Preliminary results presented at ASCO 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top